Sickle Cell Disease Stocks List

Sickle Cell Disease Stocks Recent News

Date Stock Title
May 13 FULC Fulcrum upgraded by Goldman Sachs ahead of Phase 3 data
May 13 FULC Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
May 13 FULC Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
May 13 FULC Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript
May 13 FULC Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate
May 13 FULC Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
May 13 FULC Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
May 13 FULC Fulcrum Therapeutics GAAP EPS of -$0.43 in-line
May 13 FULC Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13 FULC Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 11 BLUE bluebird bio, Inc. (BLUE) Q1 2024 Earnings Call Transcript
May 10 BLUE bluebird bio Inc (BLUE) Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Focus ...
May 10 BLUE bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
May 10 GLYC GlycoMimetics GAAP EPS of -$0.17 in-line
May 9 GLYC GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript
May 9 BLUE Bluebird bio spikes even as CRISPR leads in gene therapy rollout
May 9 FULC Fulcrum Therapeutics to Participate in Upcoming May Conferences
May 9 BLUE bluebird bio reports Q1 results
May 9 BLUE bluebird bio Reports First Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
May 9 BEAM Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Sickle Cell Disease

Sickle cell disease (SCD) is a group of blood disorders typically inherited from a person's parents. The most common type is known as sickle cell anaemia (SCA). It results in an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. This leads to a rigid, sickle-like shape under certain circumstances. Problems in sickle cell disease typically begin around 5 to 6 months of age. A number of health problems may develop, such as attacks of pain ("sickle cell crisis"), anemia, swelling in the hands and feet, bacterial infections and stroke. Long-term pain may develop as people get older. The average life expectancy in the developed world is 40 to 60 years.Sickle cell disease occurs when a person inherits two abnormal copies of the haemoglobin gene, one from each parent. This gene occurs in chromosome 11. Several subtypes exist, depending on the exact mutation in each haemoglobin gene. An attack can be set off by temperature changes, stress, dehydration and high altitude. A person with a single abnormal copy does not usually have symptoms and is said to have sickle cell trait. Such people are also referred to as carriers. Diagnosis is by a blood test, and some countries test all babies at birth for the disease. Diagnosis is also possible during pregnancy.The care of people with sickle cell disease may include infection prevention with vaccination and antibiotics, high fluid intake, folic acid supplementation and pain medication. Other measures may include blood transfusion and the medication hydroxycarbamide (hydroxyurea). A small percentage of people can be cured by a transplant of bone marrow cells.As of 2015, about 4.4 million people have sickle cell disease, while an additional 43 million have sickle cell trait. About 80% of sickle cell disease cases are believed to occur in Sub-Saharan Africa. It also occurs relatively frequently in parts of India, the Arabian Peninsula and among people of African origin living in other parts of the world. In 2015, it resulted in about 114,800 deaths. The condition was first described in the medical literature by the American physician James B. Herrick in 1910. In 1949, the genetic transmission was determined by E. A. Beet and J. V. Neel. In 1954, the protective effect against malaria of sickle cell trait was described.

Browse All Tags